AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23534896
Drug: Fexofenadine 120
RxNorm normalized name: fexofenadine hydrochloride 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 120 mg/day
Trial: 19164608
Drug: HMB/Arg/Lys supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB/Arg/Lys supplement (beta-hydroxy-beta-methylbutyrate, L-arginine, and L-lysine)
Trial: 19164608
Drug: Control supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control supplement (isonitrogenous)
Trial: 17210383
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical therapy (BMT) plus supervised exercise
Trial: 17210383
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical therapy (BMT) plus cilostazol
Trial: 17210383
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical therapy (BMT) plus supervised exercise plus cilostazol
Trial: 16338562
Drug: Placebo (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (standard postoperative therapy)
Trial: 12389073
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide without grapefruit juice
Trial: 8665721
Drug: Intranasal lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal lysine aspirin (2000 micrograms)
Trial: 2223348
Drug: Fentanyl 15
RxNorm normalized name: fentaNYL 150 mcg/30 mL-D5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 15 micrograms kg‐1 i.v. with corticotrophin releasing factor 100 micrograms i.v., growth hormone releasing hormone 100 micrograms i.v., and arginine vasopressin 10 units i.m.
Trial: 543907
Drug: mezlocillin (slow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mezlocillin (slow injection)
Trial: 30375661
Drug: Intensive‐intermittent music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive‐intermittent music therapy (4x/week, off, 4x/week, off)
Trial: 30375661
Drug: Standard spaced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard spaced protocolised music therapy (2x/week)
Trial: 28800385
Drug: New paediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New paediatric valaciclovir formulation
Trial: 28800385
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (crushed and suspended tablets)
Trial: 25727104
Drug: 0.015% ingenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015% ingenol mebutate gel (IMB) applied daily for three consecutive days
Trial: 25727104
Drug: 5% 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-fluorouracil (5-FU) cream applied twice a day for 4 weeks
Trial: 16765271
Drug: Treatment acceptability
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment acceptability and effect among compliers
Trial: 15636216
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% betaxolol
Trial: 7503497
Drug: Acyclovir, 400
RxNorm normalized name: Acyclovir, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir, 400 mg twice daily for 70 days
Trial: 1857729
Drug: Ventoline inhalation
RxNorm normalized name: Ventolin Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventoline inhalation aerosol
Trial: 1857729
Drug: Orion salbutamol
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orion salbutamol inhalation aerosol
Trial: 6409917
Drug: Ipodate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipodate (3 g on days 1 and 5 of fasting)
Trial: 6409917
Drug: T3 (5
RxNorm normalized name: Triiodothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T3 (5 μg every 4 h)
Trial: 28229457
Drug: Hydroxy progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hydroxy progesterone injection
Trial: 25683037
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec (IDeg) once daily
Trial: 25683037
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (IDet) once or twice daily
Trial: 18029469
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d rosuvastatin
Trial: 15786754
Drug: Contrast injection
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast injection at 0.07 mL/kg body weight/sec over 30 sec at an iodine concentration of 300 mgI/mL (Group 1)
Trial: 15786754
Drug: Contrast injection
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast injection at 0.06 mL/kg body weight/sec over 30 sec at an iodine concentration of 350 mgI/mL (Group 2)
Trial: 15786754
Drug: Contrast injection
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast injection at 0.07 mL/kg body weight/sec over 25.7 sec at an iodine concentration of 350 mgI/mL (Group 3)
Trial: 10349120
Drug: Saline group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline group: 0.45% saline solution I.V., 1.5 cc/kg/min, 6 hours before and after the angiographic study
Trial: 10349120
Drug: Dopa group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopa group: 0.45% saline solution I.V. plus dopamine 2 micrograms/kg/min, 30 minutes before the study until termination
Trial: 7756151
Drug: 0.05‐0.1% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05‐0.1% tretinoin cream (Retin A, Ortho)
Trial: 7756151
Drug: Purpose cream
RxNorm normalized name: Purpose Cream
DrugBank: Octisalate (DB11062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Purpose cream (vehicle control)
Trial: 2192553
Drug: Loperamide hydrochloride
RxNorm normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loperamide hydrochloride (8 mg daily dosage limit, 40 ml)
Trial: 2192553
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (4.9 g daily dosage limit)
Trial: 794716
Drug: Naltrexone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone plus behavior therapy
Trial: 31540724
Drug: Porcine dermal
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine dermal patch augmentation
Trial: 23070057
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg/day for 30 days)
Trial: 15997021
Drug: Non-selective serotonin
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective serotonin reuptake inhibitor antidepressants
Trial: 9491504
Drug: MN rgp160
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN rgp160 vaccine (200 μg doses)
Trial: 9491504
Drug: MN rgp160
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN rgp160 vaccine (800 μg fourth dose)
Trial: 9098468
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate (CC) treatment
Trial: 2759843
Drug: Group administered
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group administered CBT
Trial: 2759843
Drug: Individually administered
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually administered CBT
Trial: 2759843
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (wait list) control
Trial: 29759063
Drug: Paracetamol and
RxNorm normalized name: Paracetamol and tramadol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol and NSAIDs (specific dosages and duration not mentioned)
Trial: 25064723
Drug: Ranibizumab or
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab or Bevacizumab (both treatments)
Trial: 22774615
Drug: Shengjing Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengjing Tablets
Trial: 22774615
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E capsules (control group)
Trial: 8903629
Drug: Octreotide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (1 mu g/kg body weight subcutaneously, twice a day at 0800 and 1800 h)
Trial: 2633238
Drug: Tablet pancreatin
RxNorm normalized name: pancreatin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet pancreatin (12 tablets/day)
Trial: 323298
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg triamterene plus 25 mg hydrochlorothiazide
Trial: 323298
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg spironolactone plus 25 mg hydrochlorothiazide
Trial: 30464234
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise intervention (n = 14), three 50‐min sessions weekly from 16 weeks gestation to delivery
Trial: 24019047
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation (MBP) - one Fleet enema on the morning of surgery
Trial: 24019047
Drug: Non-mechanical bowel
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-mechanical bowel preparation (non-MBP) - no enema before surgery
Trial: 19663521
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 mg once daily for 1 year
Trial: 19663521
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg once daily for 1 year
Trial: 10980875
Drug: Platelet glycoprotein
RxNorm normalized name: PLATELET GLYCOPROTEIN VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet glycoprotein IIb/IIIa receptor blockade
Trial: 1446142
Drug: GR32191, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR32191, 40 mg four times daily for 3 weeks
Trial: 6152435
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (0.075 U/kg body weight)
Trial: 6152435
Drug: Porcine insulin
RxNorm normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine insulin (0.075 U/kg body weight)
Trial: 6152435
Drug: Bovine insulin
RxNorm normalized name: Bovine insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine insulin (0.075 U/kg body weight)
Trial: 30997499
Drug: Sucrose (1.25-1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (1.25-1.75 L of beverage sweetened with sucrose daily for 12 weeks)
Trial: 30997499
Drug: Saccharin (1.25-1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharin (1.25-1.75 L of beverage sweetened with saccharin daily for 12 weeks)
Trial: 30997499
Drug: Sucralose (1.25-1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralose (1.25-1.75 L of beverage sweetened with sucralose daily for 12 weeks)
Trial: 30997499
Drug: Aspartame (1.25-1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (1.25-1.75 L of beverage sweetened with aspartame daily for 12 weeks)
Trial: 30997499
Drug: Rebaudioside A
RxNorm normalized name: Rebaudioside A
DrugBank: Rebaudioside A (DB15136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebaudioside A (1.25-1.75 L of beverage sweetened with rebA daily for 12 weeks)
Trial: 20649060
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate with potassium salt (GS‐K) 1500 mg daily
Trial: 20649060
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate with sodium salt (GS‐Na) 1500 mg daily
Trial: 18379501
Drug: Semax (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semax (1% solution)
Trial: 12384844
Drug: Nevirapine (Nvp),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine (Nvp), stavudine (d4T), and indinavir (Idv; 1000 mg 3 times daily)
Trial: 12384844
Drug: Lamivudine (3TC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (3TC), stavudine (d4T), and indinavir (Idv; 800 mg 3 times daily)
Trial: 1809720
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser treatment (GAAS pulsed laser)
Trial: 6853932
Drug: Cortisol (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (8 mg/kg)
Trial: 28902034
Drug: 1,060-nm diode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,060-nm diode laser treatment
Trial: 24004891
Drug: Orange-fleshed sweet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange-fleshed sweet potatoes (12 mg β-carotene/d)
Trial: 24004891
Drug: Tangerines (5.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tangerines (5.3 mg β-cryptoxanthin/d)
Trial: 24004891
Drug: White-fleshed sweet
RxNorm normalized name: white sweet clover pollen extract
DrugBank: Melilotus albus pollen (DB10858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White-fleshed sweet potatoes with a vitamin A supplement (0.5 mg/d)
Trial: 20189491
Drug: MenACWY-CRM administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM administered concomitantly with Tdap and HPV vaccines
Trial: 20189491
Drug: MenACWY-CRM administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM administered sequentially with Tdap and HPV vaccines
Trial: 16981000
Drug: 2 h
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 h infusion of CsA 3 mg/kg/day
Trial: 16981000
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of CsA 3 mg/kg/day
Trial: 15239026
Drug: Repaglinide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (1 mg pre-meal 3 x/day) + Metformin (2550 mg/day)
Trial: 10908008
Drug: Research conducted
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Research conducted in community treatment organizations
Trial: 8446968
Drug: Aspirin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (two doses)
Trial: 3543037
Drug: 3 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injections of cefamandole (at induction of anesthesia and after 4 and 10 hours)
Trial: 3543037
Drug: 8 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 injections of cefamandole (at induction of anesthesia, after 4 hours, then every 6 hours up to 40 hours)
Trial: 25515692
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg of PSE in the morning (AM(PSE))
Trial: 25515692
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg of PSE in the afternoon (PM(PSE))
Trial: 25515692
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg of PSE
Trial: 16340195
Drug: Topical acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acyclovir (ACV) ointment
Trial: 16340195
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir (VACV)
Trial: 15134308
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg GH/m2/day
Trial: 15134308
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg GH/m2/day
Trial: 11561869
Drug: Enzyme treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme treatment (trypsin, chymotrypsin, and papain)
Trial: 9051139
Drug: Granisetron (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (40 micrograms/kg) plus steroids (500 mg of methylprednisolone or 8 mg of dexamethasone)
Trial: 3511184
Drug: Bilateral oophorectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral oophorectomy (crossover treatment)
Trial: 3511184
Drug: Tamoxifen (crossover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (crossover treatment)
Trial: 3511184
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to progression (initial treatment)
Trial: 29882738
Drug: Low-Level Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Level Laser Therapy (LLLT) with a wavelength of 660 nm, 30 mW power, continuous mode emission, 6 J/cm2 dosimetry, applied every 48 hours for 4 weeks.
Trial: 24576068
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of sulphadoxine-pyrimethamine (SP3)
Trial: 24576068
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of sulphadoxine-pyrimethamine (SP2)
Trial: 18603751
Drug: Amiodarone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone treatment with standard pulmonary artery catheter
Trial: 30950698
Drug: Stretch‐and‐flow voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretch‐and‐flow voice therapy (SnF)
Trial: 30950698
Drug: Resonant voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resonant voice therapy (RVT)
Trial: 16919161
Drug: SFC (50/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC (50/100 mcg)
Trial: 16919161
Drug: FBC (4.5/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBC (4.5/160 mcg)
Trial: 11350283
Drug: Low molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular-weight heparin
Trial: 3428842
Drug: Methyclothiazide 2
RxNorm normalized name: methyclothiazide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyclothiazide 2 mg alone
Trial: 3428842
Drug: Methyclothiazide 2
RxNorm normalized name: methyclothiazide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyclothiazide 2 mg with triamterene 25 mg
Trial: 3428842
Drug: Methyclothiazide 2
RxNorm normalized name: methyclothiazide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyclothiazide 2 mg with larger doses of triamterene
Trial: 25814467
Drug: PEG‐IFN‐α treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN‐α treatment
Trial: 23376601
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for treating child emotional and behavioral symptoms following trauma
Trial: 12821205
Drug: Transfer at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer at 30 mg methadone
Trial: 12821205
Drug: Transfer when
RxNorm normalized name: SET,TRANSFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer when 'uncomfortable' dosing protocol
Trial: 12821205
Drug: Transfer from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer from doses less than 30 mg methadone
Trial: 12821205
Drug: Buprenorphine induction
RxNorm normalized name: buprenorphine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine induction (first dose 4 mg)
Trial: 12845731
Drug: Aprotinin (1,000,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (1,000,000 KIU by vein injection and 2,000,000 KIU as a bolus in prime)
Trial: 7640544
Drug: Active transdermal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transdermal nicotine patches
Trial: 2565314
Drug: Clomiphene citrate,
RxNorm normalized name: ClomiPHENE Citrate, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate, 25 mg daily for 25 days with 5 days' rest each month
Trial: 2565314
Drug: Ascorbic acid,
RxNorm normalized name: ASCORBIC ACID, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascorbic acid, 500 mg daily
Trial: 26197451
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of AZD9056 administered orally as a tablet once daily for 28 days
Trial: 25607793
Drug: Skin barrier
RxNorm normalized name: Skin Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin barrier emulsion cream
Trial: 11934964
Drug: Glucosamine sulphate
RxNorm normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulphate 1500 mg daily for 6 months
Trial: 7151087
Drug: Tiapamil (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil (1.1 mg/kg)
Trial: 7151087
Drug: Tiapamil (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil (1.6 mg/kg)
Trial: 7151087
Drug: Verapamil (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (0.07 mg/kg)
Trial: 7151087
Drug: Verapamil (0.14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (0.14 mg/kg)